Role of Anti-VEGF (Bevacizumab) in Management of Neovascular Glaucoma: A Review
Abdulrahman Arshed N. Alharfy, Marwan Saleh D. Albalawi, Abdulmajeed Mousa Alzahrani, Ruby Naif M. Alsubaie, Amani Ahmad S. Albalawi, Waad Ali Alkaabneh, Abdullah Ibrahim Altidlawi, Amal Nafea J. Alharbi, Afnan Mohammed H. Almutairi, Rola Ali S. Alotabi
Journal of Pharmaceutical Research International · pp. 215–221 · Published 6 Aug 2021
10.9734/jpri/2021/v33i40A32237Abstract
Neovascular glaucoma (NVG) is an aggressive type of glaucoma, which often results in poor visual outcomes. Antivascular endothelial growth factor is frequently used for various conditions in which VEGF release is induced in response to retinal ischemia. Bevacizumab is a humanized anti-VEGF monoclonal IgG1 antibody. The potential of antivascular endothelial growth factor (anti-VEGF) agents to modify the disease course of neovascular glaucoma (NVG) was recognized shortly after their use in the treatment of age-related macular degeneration was reported. These medications were noted to induce rapid regression of the anterior segment neovascularization that characterizes NVG. Several studies as well as extensive clinical experience have demonstrated a rapid regression of anterior segment neovascularization following the injection of anti-VEGF agents. This review aims to summarize current evidences regarding effectiveness of Bevacizumab in management of neovascular glaucoma.
Cited by 0
No indexed citations yet.
Related research
- The Controversies Surrounding Bevacizumab and Ranibizumab — shares topic coverage
- Relationship of Hemoglobin A1C and Outcomes of Treatment of Diabetic Macular Edema — shares topic coverage
- Recurrent Radiation Retinopathy and Optic Neuropathy after Cranial Irradiation Therapy Treated by Intravitreal Bevacizumab — shares topic coverage
- Repeated Intravitreal Bevacizumab Injections versus Single Combined Intravitreal Bevacizumab and Posterior Subtenon Triamcinolone Injections for Treatment of Diabetic Macular Edema — shares topic coverage
- Therapeutic Efficacy of Intravitreal Bevacizumab (Avastin)® in Patients with Parafoveal Telangiectasia Type II Complicated by Choroidal Neovascular Membrane and/or Cystoid Macular Edema — shares topic coverage
Article metrics
Real usage data collected on this platform.
0
Page views
0
PDF downloads
0
Outbound clicks
0
Citations
Views by country
Approximate, from request IP at view time — not citizenship or institution. Countries with fewer than 5 views are grouped as "Other".
No views recorded yet.
Traffic sources
Referring site, by host.
No traffic recorded yet.
Views and downloads exclude known bots/crawlers. Citations combines this platform's own DOI-resolved index with each external source's own reported total — see Cited by above for individually listed citing works. Last refreshed 0 seconds ago.